Baricitinib

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How is baricitinib supplied for the treatment of COVID-19

Baricitinib is supplied as 1-mg, 2-mg, and 4-mg tablets for the emergency use of treatment of COVID-19 in hospitalized patients..

US_cFAQ_BAR019G_HOW_SUPPLIED_COVID-19
cFAQ
cFAQ
US_cFAQ_BAR019G_HOW_SUPPLIED_COVID-19
en-US

Baricitinib Emergency Use Authorization for COVID-19

Baricitinib has not been approved, but has been authorized for emergency use by FDA for the treatment of COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.

Baricitinib is authorized for the treatment of COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the baricitinib under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

For information on the authorized use of baricitinib and mandatory requirements under the EUA, please review the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients/Caregivers at baricitinibemergencyuse.com.

How Supplied

Baricitinib for oral administration is available as debossed, film-coated, immediate-release tablets. Each tablet contains a recessed area on each face of the tablet surface.1

Under this emergency use authorization, baricitinib is supplied in 30 count bottles as follows:

  • OLUMIANT (baricitinib) tablet 1 mg (NDC 0002-4732-30)
  • OLUMIANT (baricitinib) tablet 2 mg (NDC 0002-4182-30), and
  • baricitinib tablet 4 mg (NDC 0002-6885-30).1

Storage and Handling

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).1 

References

1U. S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers. Emergency Use Authorization (EUA) of Baricitinib. 2021.

Date of Last Review: November 08, 2021


Contact Lilly

Call Us

If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.

Daily Live Support: 9am to 7pm ET.
After Hours: Call Back Support Available

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical